This site is intended for Healthcare Professionals.

Galapagos Butterfly logo

A state of transformation:

Galapagos-sponsored Symposia and Meet-the-Expert sessions at ECCO 2021

Details of Galapagos activities at the 16th Congress of ECCO and information about the company can be found below

Fish icon in circle

About Galapagos

Pioneering for patients.

  • We are Galapagos. A commercial-stage biotechnology company.
  • We have more than 1,200 employees worldwide.
  • We specialise in the discovery and development of small molecule medicines with novel modes of action.
  • Our pipeline comprises early discovery through to Phase 3 programmes with a focus on inflammation and fibrosis.
  • Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialisation of innovative medicines that will improve people's lives.
Fish illustration

We discover.
We dare.
We care.

Follow us on our journey twitter icon linked in icon globe icon
Woman looking into microscope

Would you like to receive updates via e-mail on Galapagos’ IBD services and developments?
Sign up for Galapagos news and views

Sign up now
Fish icon in circle

We see what UC: time for a holistic approach to remission

A Galapagos sponsored symposium taking place during the ECCO 2021 virtual congress

Thursday 8 July, 17:55–18:55 CEST


The symposium will aim to introduce and define the concept of holistically approaching remission and explain why this is important for improving outcomes in patients with UC. The session will comprise three short, discursive presentations followed by a live Q&A.

Panellists will examine how UC impacts the everyday lives of patients and which holistic treatment goals should be considered to optimise quality of life. The session will review unmet needs in UC care and consider how physicians can incorporate patient-important outcomes when making treatment decisions. Speakers will also share best practice examples for how to optimise patient care in the context of novel management options and an adapting world, including shared decision making and optimal use of telemedicine. The presentations will be complemented by an illustrative patient case study to contextualise discussions.


Watch the introductory video to the Galapagos organised and funded symposium at ECCO 2021

Fish icon in circle

Meet the Speakers

Professor Axel Dignass (Chair)

Location icon Agaplesion Markus Hospital, Goethe University, Frankfurt, Germany

Prof. Dignass, MD, PhD, is Director of the Department of Medicine and Professor of Medicine and Gastroenterology at the Agaplesion Markus Hospital, Goethe University in Frankfurt, Germany.

Professor Charlie Lees

Location icon University of Edinburgh, Edinburgh, UK

Prof. Lees is Professor of Gastroenterology at the University of Edinburgh, a UK Research and Innovation Future Leaders Fellow (UKRIFLF) and Consultant Gastroenterologist in the Edinburgh IBD Unit.

Professor Mathurin Fumery

Location icon Amiens University Hospital, University of Picardy Jules Verne, Amiens, France

Prof. Fumery, MD, PhD, is a consultant gastroenterologist at the University of Picardy Jules Verne and is Professor of Gastroenterology at Amiens University Hospital in Amiens, France.

Fish icon in circle


  • icon shows item is  minutes long

    Welcome and introduction

    Professor Axel Dignass

    Professor Axel Dignass will open the meeting with a short introduction to the symposium and the speakers, and will introduce an illustrative patient case study that will be used throughout the symposium to contextualise disease impacts, treatment decisions and outcomes

  • icon shows item is  minutes long

    Eyes on the prize: defining what holistically approaching remission means for our patients

    Full faculty discussion

    This session will start by examining the concept of holistically approaching remission and what it means for patients. The faculty will then discuss how UC impacts overall patient health and consider treatment goals that can help facilitate a return to true health, contextualised through the patient case study introduced in the previous session

  • icon shows item is  minutes long

    Looking deeper: contextualising treatment decisions from the perspective of holistic health

    Professor Charlie Lees

    Professor Charlie Lees will discuss how novel treatment options may benefit patients’ overall wellbeing, and how choosing the right treatment and understanding patient-important outcomes can facilitate a return to holistic health beyond symptom control

Additional information

Would you like to receive updates via e-mail on Galapagos’ IBD services and developments?
Sign up for Galapagos news and views

Sign up now

Code: GL-IBD-NA-202105-00016
Date of preparation: May 2021

GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos NV. © 2021 Galapagos NV. All rights reserved.
This programme is not affiliated with ECCO.